相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Investigation of the Rate-Determining Process in the Hepatic Elimination of HMG-CoA Reductase Inhibitors in Rats and Humans
Takao Watanabe et al.
DRUG METABOLISM AND DISPOSITION (2010)
Membrane transporters in drug development
Kathleen M. Giacomini et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Effects of a Concomitant Single Oral Dose of Rifampicin on the Pharmacokinetics of Pravastatin in a Two-Phase, Randomized, Single-Blind, Placebo-Controlled, Crossover Study in Healthy Chinese Male Subjects
Sheng Deng et al.
CLINICAL THERAPEUTICS (2009)
In vitro-in vivo Extrapolation of Transporter-mediated Clearance in the Liver and Kidney
Hiroyuki Kusuhara et al.
DRUG METABOLISM AND PHARMACOKINETICS (2009)
The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling
Motohiro Kato et al.
PHARMACEUTICAL RESEARCH (2008)
Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans
Soichiro Matsushima et al.
DRUG METABOLISM AND DISPOSITION (2008)
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin
M. K. Pasanen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Bosentan is a substrate of human OATP1B1 and OATP1B3:: Inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin a, rifampicin, and sildenafil
Alexander Treiber et al.
DRUG METABOLISM AND DISPOSITION (2007)
Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers
Y. Y. Lau et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the cocktail approach
U. Fuhr et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Drug-drug interaction between pitavastatin and various drugs via OATP1B1
Masaru Hirano et al.
DRUG METABOLISM AND DISPOSITION (2006)
Molecular characterization and inhibition of amanitin uptake into human hepatocytes
K Letschert et al.
TOXICOLOGICAL SCIENCES (2006)
Transporters as a determinant of drug clearance and tissue distribution
Y Shitara et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034
J Sahi et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2006)
Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: Application of in vitro and ex situ systems
YY Lau et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro:: Effect of fibrates and rifampicin
LI Kajosaari et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2005)
Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells
Y Kameyama et al.
PHARMACOGENETICS AND GENOMICS (2005)
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes:: Consequences for pravastatin pharmacokinetics
Y Nishizato et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation
RG Tirona et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Clinical pharmacokinetics of atorvastatin
H Lennernas
CLINICAL PHARMACOKINETICS (2003)
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver
SR Vavricka et al.
HEPATOLOGY (2002)
Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin
AL Mazzu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
分享论文
